270
Client Alert | 1 min read | 03.02.06
In M. Eagles Tool Warehouse, Inc. (d/b/a S&G Tool Aid Corp.) v. Fishing Tooling Company, Inc. (d/b/a Astro Pneumatic Tool Co., (No. 05-1224, -1228, February 27, 2006) , the Federal Circuit reverses a district court's grant of summary judgment that a patent is unenforceable due to inequitable conduct. The summary judgment motion asserted that patent was unenforceable for not disclosing information regarding the 20- year selling of a predecessor product to the PTO. The district court found that the information was material because the predecessor product contained claim limitations that the patent examiner held not to be found in the prior art and inferred an intent to deceive from a lack of good faith explanation for not disclosing that prior sale information.
In reversing, the Federal Circuit panel states that intent to deceive cannot be inferred solely from the fact that information was not disclosed; but that there must be a factual basis for a finding of deceptive intent. That is, a failure to disclose prior art to the patent examiner, where the only evidence of intent is a lack of a good faith explanation for the nondisclosure, cannot by itself constitute clear and convincing evidence sufficient to support a determination of culpable intent. To satisfy the requirement of the intent to deceive element of inequitable conduct, the involved conduct, viewed in light of all the evidence of good faith, must indicate sufficient culpability to require a finding of intent to deceive.
[http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/05-1224.pdf].
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
